Search research articles
Contact Us
Filters
Showing results (101-110 of 118) with videos related to
Page
of 12
Sort By:
Oral Oncology
|
August 13, 2021
Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer
Andrée Boucher, Shereen Ezzat, Sebastien Hotte, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Paul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Oncotarget
|
October 21, 2017
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, et al.
The Journal of Molecular Diagnostics : JMD
|
April 3, 2022
The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space
Tammy T Y Lau, Zahra J Sefid Dashti, Emma Titmuss, et al.
Cancer Research Communications
|
December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Cold Spring Harbor Molecular Case Studies
|
December 6, 2018
Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer
Erica S Tsang, Yaoqing Shen, Negar Chooback, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society
|
September 4, 2016
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer
Brandon S Sheffield, Regan Fulton, Steve E Kalloger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
Nature Medicine
|
October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
NPJ Precision Oncology
|
June 7, 2018
Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma
My Linh Thibodeau, Melika Bonakdar, Eric Zhao, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 118) with videos related to
Sort By:
Page
of 12
Oral Oncology
|
August 13, 2021
Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer
Andrée Boucher, Shereen Ezzat, Sebastien Hotte, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 20, 2025
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study
Paul Wheatley-Price, Vishal Navani, Aliyah Pabani, et al.
Oncotarget
|
October 21, 2017
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196
Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, et al.
The Journal of Molecular Diagnostics : JMD
|
April 3, 2022
The Neoantigen Landscape of the Coding and Noncoding Cancer Genome Space
Tammy T Y Lau, Zahra J Sefid Dashti, Emma Titmuss, et al.
Cancer Research Communications
|
December 5, 2024
Clonal Hematopoiesis of Indeterminate Potential and its Association with Treatment Outcomes and Adverse Events in Patients with Solid Tumors
Tharani Krishnan, Joao Paulo Solar Vasconcelos, Emma Titmuss, et al.
Cold Spring Harbor Molecular Case Studies
|
December 6, 2018
Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer
Erica S Tsang, Yaoqing Shen, Negar Chooback, et al.
The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society
|
September 4, 2016
Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer
Brandon S Sheffield, Regan Fulton, Steve E Kalloger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 18, 2009
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
Glenwood D Goss, Andrew Arnold, Frances A Shepherd, et al.
Nature Medicine
|
October 9, 2023
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Valsamo Anagnostou, Cheryl Ho, Garth Nicholas, et al.
NPJ Precision Oncology
|
June 7, 2018
Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma
My Linh Thibodeau, Melika Bonakdar, Eric Zhao, et al.
Page
of 12